Sermorelin vs Tesamorelin: What Separates Them

Two drugs with the same mechanism and completely different standing. One is currently approved and carries a maintained label; the other has neither. And the approved one’s labelling contains a sentence that undercuts the main reason people go looking for either.

One of twoIs currently approved in the United States. It is not sermorelin
LipodystrophyThe only condition tesamorelin is approved to treat, in HIV-infected adults
Weight neutralHow tesamorelin’s own labelling describes its effect on weight
NeitherIs approved for ageing, muscle gain, recovery or general wellbeing

The short version

Sermorelin and tesamorelin are both growth hormone-releasing hormone analogues. Both prompt the pituitary to release growth hormone rather than supplying the hormone directly. From there they diverge almost completely.

Tesamorelin is an approved medicine with a current label, a defined indication and a documented safety profile. Sermorelin’s approvals were withdrawn in 2009 and what is dispensed now is compounded. If you are comparing them because you have been offered one of them, that difference is the substance of the comparison — and it is not the difference most pages lead with.

Same class, opposite standing

Tesamorelin — approved and marketed. Sold as Egrifta, licensed under BLA 022505 and held by Theratechnologies. It is a biologic, dispensed as a powder for reconstitution, prescription-only. It has a current FDA label, which means a maintained adverse reactions section, warnings and contraindications.
Sermorelin — withdrawn, then compounded. Approved twice, under NDA 19-863 in 1990 and NDA 20-443 in 1997, both withdrawn effective June 2009 at the manufacturer’s request. The FDA confirmed in 2013 that the withdrawal was not for reasons of safety or effectiveness. No approved product exists today; pharmacies compound it. Full history on the sermorelin overview.

Worth knowing

Withdrawn is not the same as banned, and it is not the same as unapproved-and-never-studied. Sermorelin passed the approval bar twice and left the market commercially. That is a better position than most compounds in this market — and still a materially worse one than holding a live approval.

What each one was approved to do

This is where the comparison gets useful, because neither indication resembles what either compound is marketed for online.

Tesamorelin, from the label

“EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.”

That is a narrow indication for a specific complication in a specific population. Lipodystrophy in this context is an abnormal redistribution of body fat associated with HIV and its treatment, and the drug was developed to address the visceral fat accumulation that comes with it. It is not a body composition drug for the general population.

Sermorelin’s two approvals were narrower still, and both are described in our overview: treatment of idiopathic growth hormone deficiency in children with growth failure, and, separately, evaluation of the pituitary’s ability to secrete growth hormone. A paediatric treatment and a diagnostic test.

What neither covers

Between three FDA approvals across two compounds, not one covers ageing, athletic recovery, muscle gain, sleep quality, or general adult wellbeing. Every use of that kind is outside what was ever approved, for both drugs.

The weight loss claim, refused by its own label

A great deal of the marketing around both compounds turns on fat loss and body recomposition. Tesamorelin is the one drug in this class where that claim can be checked against an FDA-reviewed document, and the document addresses it directly, in a section headed Limitations of Use.

Limitations of use, verbatim

“EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect.”

Read carefully, that is a precise statement rather than a blanket denial. Tesamorelin reduces visceral abdominal fat in the population it was studied in; what it does not do is reduce body weight. Fat can be redistributed without the number on the scale moving. The label is drawing exactly that distinction, and it is drawing it because the difference is real and had to be stated.

The same section adds that “long-term cardiovascular safety of EGRIFTA SV has not been established,” and advises considering the risk and benefit of continuing in patients who have not seen a reduction in visceral adipose tissue. A drug that works for a defined purpose, with an open question about what years of it do.

Why this matters for sermorelin

Sermorelin has no label to make or refuse a weight claim. The closest evidence available is that the approved drug working through the same mechanism was found to be weight neutral, and had to say so. That is not proof about sermorelin. It is the only checkable data point in the vicinity.

One has documentation, the other has history

The most practical difference between these two is not pharmacological. It is that one of them comes with a document telling you what to watch for, and the other does not.

Tesamorelin’s label carries warnings for increased risk of neoplasms, elevated IGF-1 with the note that “the effects of prolonged elevations in IGF-1 levels are unknown,” fluid retention, glucose intolerance or diabetes, hypersensitivity reactions and injection site reactions. It lists the reactions reported above five percent. It tells a prescriber to monitor IGF-1 and to stop if there is evidence of recurrent malignancy.

Sermorelin has none of that, because a label belongs to an approval and the approvals are gone. We searched the FDA’s label database and found nothing for it. What exists instead is the agency’s 2013 review, which looked at post-marketing adverse event data and found nothing indicating the drug had been withdrawn for safety. That is reassuring as far as it goes, and it is not a safety profile. Our sermorelin side effects page sets out the whole record.

What the comparison actually settles

Most versions of this comparison are framed as which is stronger or which works better. That framing assumes a body of head-to-head evidence that does not exist. No trial we could find compares sermorelin against tesamorelin for any outcome.

What the comparison does settle is narrower and more useful:

Tesamorelin has an approval, a label and a defined population. Sermorelin has none of those at present.
The approved drug in this class reduces visceral fat in one specific condition, and is weight neutral.
Regulators consider this mechanism to warrant monitoring for malignancy, IGF-1, fluid retention and glucose handling.
Neither drug has an approval covering the reason most people are reading about them.

If someone is offering you a choice between them, those four points are the ones worth raising with whoever is prescribing.

What this page will not tell you

Which of the two you should take. Both are prescription decisions, and one of them is approved only for a condition that has to be diagnosed.
How much of either to use, or how they compare on amount. No completed trial establishes an equivalence and we do not publish protocols.
Which is cheaper, or where to obtain either. We do not track pricing on compounded products and do not link to suppliers.
Which is more effective. There is no head-to-head trial, so any answer would be invented.

Sources and method

Tesamorelin. The current FDA labelling for Egrifta, licensed under BLA 022505 and held by Theratechnologies, read through openFDA. The indication, the Limitations of Use, the warnings and the adverse reactions are quoted from that label, which refers to the product as EGRIFTA SV.
Sermorelin. Determination That GEREF (Sermorelin Acetate) Injection … Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, Federal Register, 4 March 2013, for the application numbers, approval dates, indications and withdrawal.
The absence of a sermorelin label. We queried the FDA labelling database for sermorelin and it returned no matches, which is what the 2009 withdrawal predicts.
What we could not verify. We found no trial comparing the two compounds directly, but a search of one registry cannot prove none exists. We have not read the tesamorelin clinical trial reports, only its labelling, so we describe what the label states rather than assessing the underlying data. We have not established what any compounded sermorelin product contains.
Method. Where one drug has documentation and the other does not, this page says so rather than filling the gap with inference. Evidence about tesamorelin is labelled as being about tesamorelin, every time it appears.

Sermorelin overview → Sermorelin side effects → How we source and verify →

FDA label and Federal Register sources checked 30 August 2026. We recheck this page if either compound’s status changes.